

Consumer Economic Loss Class Action Settlement Summary Notice

If you are an individual who paid any amount of money for retail purchases of Valsartan medication manufactured by Hetero and distributed by Camber Pharmaceuticals from May 1, 2018 to July 31, 2018, you could receive a payment from a class action settlement.

A Settlement has been reached in an economic loss class action lawsuit against Hetero Drugs, Ltd., Hetero Labs Ltd., Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively “Hetero Defendants”). The settlement is part of a larger lawsuit called *In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation*, Case No. 1:19-md-02875 (MDL No. 2875) (the “Lawsuit”) and is currently pending in the United States District Court for the District of New Jersey (“the Court”). The Settlement resolves claims that Hetero Defendants violated state laws by manufacturing, distributing, selling and/or dispensing Valsartan or Valsartan containing drugs (“VCDs”) that were contaminated with a probable human carcinogen in the form of N-nitrosodimethylamine (“NDMA”), causing economic loss to the class. The Hetero Defendants have denied any wrongdoing, have denied that the amounts of NDMA or NDEA in the Valsartan and VCDs at issue were or could be carcinogenic, and have asserted various legal and factual defenses to the claims asserted on behalf of the Classes.

The Court has not decided whether the Hetero Defendants did anything wrong or whether the Plaintiffs’ claims have merit. This Settlement of Valsartan economic loss claims does not include or affect any other claims against the Hetero Defendants or any other entity, including but not limited to medical monitoring and personal injury claims. Please read this notice carefully. Your legal rights are affected whether you act or don’t act.

A federal court directed that this Notice be provided to you. The Court authorized and specifically required notice to be provided by email or text message, where available, or U.S. mail in certain limited circumstances.

Who is Included?

The Settlement Class includes all individuals and third-party-payors in the United States and its territories and possessions who paid any amount of money for retail purchases of Valsartan finished drug formulations utilizing Hetero Process III Valsartan active pharmaceutical ingredient (“API”) which was sold between May 1, 2018 and July 31, 2018. A separate notice has been sent to third-party payors.

Detailed information regarding the Class and how to determine your eligibility is available on the Settlement Website www.SartanMedicationSettlement.com.

What Does the Settlement Provide?

Hetero Defendants will pay \$11,365,489.80, which amount was established based on the total quantity of eligible Valsartan pills sold in the United States during the established period. The settlement funds will be available for distribution to the Settlement Class, after deduction of any attorneys’ fees, expenses, and class representative service awards that may be ordered by the Court. Total payments to Consumers will be capped at 40% of the net Hetero Economic Loss Class Settlement fund and each valid Consumer member of the class shall generally receive no more than \$40 for each 30-day supply purchased and no

more than a total of \$120 per Consumer. However, a Consumer member of the class who can sufficiently document, through receipts or pharmacy records, a claim in excess of \$40 for a 30-day supply paid in full by that Consumer, may receive a payment in excess of \$40 for that 30-day supply without regard to the \$40 or \$120 caps. Full details, including limitations may be found at www.SartanMedicationSettlement.com.

What Are My Rights And Options?

Submit a Claim: To receive a Settlement payment, you must submit a Claim Form. You can submit your Claim online at the Settlement Website or download a paper form to mail in. If possible, include documents to support your claim. The Administrator may contact you for pharmacy proof if needed. Full details are on the website. Your Claim Form must be **submitted online or postmarked by June 2, 2026**.

Do Nothing: If you do nothing, you will remain a part of the Class and Settlement. You will receive no payment under the Settlement and you will give up your rights to sue the Hetero Defendants about the issues in this case.

Opt-Out: Excluding yourself is the only way to keep your right to sue the Hetero Defendants over the claims in this case. You won't be bound by the Settlement, but you also won't receive any payment from it, if one is awarded. To opt-out, you must submit an exclusion request to the Settlement Administrator **postmarked or emailed and received no later than June 2, 2026**.

Object: If you do not like any part of the Settlement, you can object by writing to the Court. You cannot submit both an exclusion request and objection. To object, you must remain a Class Member. If the Court grants Final Approval over your objection, you will give up your rights to sue the Hetero Defendants about the issues in this case. If you also wish to receive payment, you must submit a Claim Form. Your objection must be **postmarked no later than June 2, 2026**.

Complete details about your rights, including detailed requirements to submit a Claim, exclude yourself/opt-out, and to object to the Settlement are available on the Settlement Website www.SartanMedicationSettlement.com.

Do I have a lawyer in this case? Yes, if you do not exclude yourself by opting out. The Court has appointed John R. Davis, Esq., Slack Davis Sanger LLP, Ruben Honik, Esq., Honik Law, and Conlee S. Whiteley, Esq., Kanner & Whiteley, LLP to represent the Consumer Economic Loss Class.

Where can I get more information? This is only a summary. For more information visit the Settlement Website or call the number below

PLEASE DO NOT WRITE OR CALL THE COURT OR THE CLERK'S OFFICE FOR INFORMATION.

www.SartanMedicationSettlement.com

1-866-875-9644